Enliven Therapeutics (NASDAQ:ELVN) Earns Outperform Rating from Analysts at William Blair

William Blair assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note published on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock.

Other equities analysts have also issued reports about the stock. JonesTrading increased their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Stifel Nicolaus boosted their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Mizuho increased their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, HC Wainwright lifted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $75.00.

Enliven Therapeutics Stock Performance

ELVN opened at $58.92 on Tuesday. Enliven Therapeutics has a one year low of $14.78 and a one year high of $62.32. The company has a market cap of $4.32 billion, a P/E ratio of -35.28 and a beta of 0.27. The business’s 50-day simple moving average is $52.72 and its 200-day simple moving average is $41.84.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, analysts predict that Enliven Therapeutics will post -1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the sale, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 196,849 shares of company stock worth $11,344,257. 3.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ELVN. Commodore Capital LP raised its holdings in shares of Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after buying an additional 17,809 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Enliven Therapeutics during the second quarter worth about $221,255,000. Vestal Point Capital LP increased its position in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the period. Polar Capital Holdings Plc increased its position in Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after acquiring an additional 418,673 shares during the period. Finally, Vanguard Group Inc. raised its stake in Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after acquiring an additional 142,378 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.